Atogepant Clinical Trials (2026): 26 Studies for Episodic Migraine & Chronic Migraine
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
26 Atogepant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Episodic Migraine & Chronic Migraine) and 15,361 total planned enrollment. 16 Phase 3 Atogepant trials, 2 Phase 4 are listed. 7 Atogepant clinical trials are actively recruiting at 93 U.S. sites across 30 states. Most recent activity: NCT05707949 (Apr 2032).
Where to Participate: All Atogepant Trial Sites in the U.S. (93 sites across 30 states)
Every actively recruiting Atogepanttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Rehabilitation & Neurological Services /ID# 248517 | Huntsville35805-4046 | NCT05711394 | Map |
| AL | Rehabilitation and Neurological Services /ID# 270782 | Huntsville35805 | NCT06810505 | Map |
| AL | The Center for Clinical Trials - Saraland /ID# 271604 | Saraland36571 | NCT05711394 | Map |
| AZ | Northern Arizona Healthcare | Flagstaff86001 | NCT06972056 | Map |
| AZ | Mayo Clinic Arizona | Phoenix85054 | NCT06972056 | Map |
| AR | Preferred Research Partner, Inc /ID# 270389 | Little Rock72211 | NCT06810505 | Map |
| AR | Preferred Research Partners /ID# 249729 | Little Rock72211 | NCT05711394 | Map |
| CA | Advanced Research Center /ID# 251381 | Anaheim92805 | NCT05711394 | Map |
| CA | Advanced Research Center /ID# 270257 | Anaheim92805 | NCT06810505 | Map |
| CA | Neuro Pain Research Center /ID# 271048 | Fresno93710 | NCT06810505 | Map |
| CA | Accellacare - Long Beach /ID# 270398 | Long Beach90807 | NCT06810505 | Map |
| CA | Alliance for Research Alliance for Wellness /ID# 248521 | Long Beach90807 | NCT05711394 | Map |
| CA | Clinical Research Institute | Los Angeles90048 | NCT06972056 | Map |
| CA | USC Keck | Los Angeles90033 | NCT06972056 | Map |
| CA | Excell Research /ID# 270258 | Oceanside92056 | NCT06810505 | Map |
| CA | Excell Research, Inc /ID# 247532 | Oceanside92056 | NCT05711394 | Map |
| CA | Desert Physicians Medical Group | Palm Springs92262 | NCT06972056 | Map |
| CA | The Neurology Group | Pomona91767 | NCT06972056 | Map |
| CA | Lumos Clinical Research Center /ID# 249731 | San Jose95124-4108 | NCT05711394 | Map |
| CA | Lumos Clinical Research Center /ID# 270582 | San Jose95124 | NCT06810505 | Map |
| CA | Sunwise Clinical Research /ID# 248529 | Walnut Creek94596 | NCT05711394 | Map |
| CA | Sunwise Clinical Research /ID# 270431 | Walnut Creek94596 | NCT06810505 | Map |
| CO | University of Colorado Anschutz Medical Campus | Aurora80045 | NCT06972056 | Map |
| FL | Northwest Florida Clinical Research Group, LLC /ID# 251382 | Gulf Breeze32561-4495 | NCT05711394 | Map |
| FL | Northwest Florida Clinical Research Group, LLC /ID# 270833 | Gulf Breeze32561 | NCT06810505 | Map |
| FL | Memorial Healthcare | Hollywood33021 | NCT06972056 | Map |
| FL | Mayo Clinic Florida | Jacksonville32066 | NCT06972056 | Map |
| FL | Apple Med Research | Miami33126 | NCT06972056 | Map |
| FL | My Preferred Research /ID# 270312 | Miami33155 | NCT06810505 | Map |
| FL | My Preferred Research LLC /ID# 249720 | Miami33155 | NCT05711394 | Map |
| FL | Encore Medical Research - Weston /ID# 271139 | Weston33331 | NCT06810505 | Map |
| FL | Pediatric Neurology & Epilepsy Center Of Central Florida - Winter Park /ID# 275263 | Winter Park32789 | NCT06810505 | Map |
| GA | Coastal Georgia Child Neurology /ID# 249733 | Brunswick31520-1601 | NCT05711394 | Map |
| IN | Deaconess Midtown Hospital /ID# 270572 | Evansville47710 | NCT06810505 | Map |
| IN | Deaconess Clinic - Gateway Health Center /ID# 247589 | Newburgh47630 | NCT05711394 | Map |
| MA | Clinical Trials of New England | Hyde Park02136 | NCT06972056 | Map |
| MI | Michigan Headache & Neurological Institute (MHNI) /ID# 247468 | Ann Arbor48104-5131 | NCT05711394 | Map |
| MI | Michigan Headache & Neurological Institute /ID# 270942 | Ann Arbor48104 | NCT06810505 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06972056 | Map |
| MS | Proven Endpoints LLC /ID# 258066 | Ridgeland39157 | NCT05711394 | Map |
| MS | Proven Endpoints LLC /ID# 270269 | Ridgeland39157 | NCT06810505 | Map |
| MO | Washington University St Louis | St Louis63110 | NCT06972056 | Map |
| NE | Nebraska Medical Center | Omaha68198 | NCT06972056 | Map |
| NE | Cct Research - Papillion Research Center /ID# 270393 | Papillion68046 | NCT06810505 | Map |
| NE | Cognitive Clinical Trials (CCT) - Papillion /ID# 248536 | Papillion68046-4131 | NCT05711394 | Map |
| NV | Advanced Research Institute Reno | Reno89511 | NCT06972056 | Map |
| NH | Healthy Perspectives - Innovate Mental Health Services /ID# 270847 | Nashua03060 | NCT06810505 | Map |
| NJ | JFK Neuroscience Institute | Edison08820 | NCT06972056 | Map |
| NJ | Goryeb Childrens Hospital /ID# 249724 | Morristown07960 | NCT05711394 | Map |
| NY | Dent Neurologic Institute - Amherst /ID# 248534 | Amherst14226 | NCT05711394 | Map |
| NY | Dent Neurologic Institute - Amherst /ID# 270260 | Amherst14226 | NCT06810505 | Map |
| NY | Nuvance Health Institute | Kingston12401 | NCT06972056 | Map |
| NY | Northwell Health | Manhasset11030 | NCT06972056 | Map |
| NY | Mt Sinai Icahn School of Medicine | New York10029 | NCT06972056 | Map |
| NC | Headache Wellness Center /ID# 251018 | Greensboro27405 | NCT05711394 | Map |
| NC | Headache Wellness Center /ID# 270568 | Greensboro27405 | NCT06810505 | Map |
| NC | Wake Forest University Health | Winston-Salem27157 | NCT06972056 | Map |
| OH | Cincinnati Childrens Hospital Medical Center /ID# 258070 | Cincinnati45229 | NCT05711394 | Map |
| OH | Patient Priority Clinical Sites, LLC /ID# 247535 | Cincinnati45215-2123 | NCT05711394 | Map |
| OH | Ohio State University Wexner Medical Center | Columbus43210 | NCT06972056 | Map |
| OK | Lynn Institute of Oklahoma City /ID# 247600 | Oklahoma City73112 | NCT05711394 | Map |
| OR | Advanced Research Institute | Portland97223 | NCT06972056 | Map |
| PA | Children's Hospital of Philadelphia - Main /ID# 258071 | Philadelphia19104-4319 | NCT05711394 | Map |
| PA | University of Pennsylvania | Philadelphia19107 | NCT06972056 | Map |
| PA | Frontier Clinical Research - Scottdale /ID# 270854 | Scottdale15683 | NCT06810505 | Map |
| PA | Frontier Clinical Research - Smithfield /ID# 270849 | Smithfield15478 | NCT06810505 | Map |
| RI | Brown University Health | Providence02903 | NCT06972056 | Map |
| TN | Le Bonheur Children's Hospital /ID# 261084 | Memphis38103 | NCT05711394 | Map |
| TN | Access Clinical Trials Inc /ID# 270280 | Nashville37203 | NCT06810505 | Map |
| TN | Access Clinical Trials, Inc. /ID# 248532 | Nashville37203 | NCT05711394 | Map |
| TN | Vanderbilt Medical Center | Nashville37215 | NCT06972056 | Map |
| TX | FutureSearch Trials of Neurology /ID# 247470 | Austin78731 | NCT05711394 | Map |
| TX | UT Health Austin at Dell Children's Neurology Clinic /ID# 264082 | Austin78723-3079 | NCT05711394 | Map |
| TX | UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577 | Austin78723-3079 | NCT06810505 | Map |
| TX | 3A Research - East El Paso /ID# 248516 | El Paso79925-7945 | NCT05711394 | Map |
| TX | Earle Research /ID# 248501 | Friendswood77546 | NCT05711394 | Map |
| TX | Earle Research /ID# 270424 | Houston77058 | NCT06810505 | Map |
| TX | DHR Health Headache Center | McAllen78504 | NCT06972056 | Map |
| TX | Family Psychiatry of The Woodlands /ID# 249727 | The Woodlands77381 | NCT05711394 | Map |
| TX | ClinPoint Trials /ID# 248540 | Waxahachie75165-1430 | NCT05711394 | Map |
| TX | Clinpoint Trials /ID# 270261 | Waxahachie75165 | NCT06810505 | Map |
| UT | Pantheon Clinical Research /ID# 251601 | Bountiful84010-4968 | NCT05711394 | Map |
| UT | Pantheon Clinical Research /ID# 270259 | Bountiful84010 | NCT06810505 | Map |
| UT | Alpine Research Organization - Clinton /ID# 276497 | Clinton84015 | NCT05711394 | Map |
| UT | Alpine Research Organization - Clinton /ID# 276527 | Clinton84015 | NCT06810505 | Map |
| UT | Advanced Research Institute Ogden | Ogden84405 | NCT06972056 | Map |
| UT | Highland Clinical Research /ID# 247590 | Salt Lake City84124 | NCT05711394 | Map |
| UT | Highland Clinical Research /ID# 270281 | Salt Lake City84124 | NCT06810505 | Map |
| VA | Office of Maria Ona /ID# 249738 | Franklin23851 | NCT05711394 | Map |
| WV | Frontier Clinical Research - Kingwood /ID# 271053 | Kingwood26537 | NCT06810505 | Map |
| WV | West Virginia University | Morgantown26506 | NCT06972056 | Map |
| WI | Marshfield Clinic Research Institute | Marshfield54449 | NCT06972056 | Map |
| WI | The Medical College of Wisconsin | Milwaukee53226 | NCT06972056 | Map |
Atogepant clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | unknown | Total |
|---|---|---|---|---|---|---|
| P1 | 2 | 2 | ||||
| P2/P3 | 1 | 1 | ||||
| P3 | 2 | 3 | 1 | 10 | 16 | |
| P4 | 1 | 1 | 2 | |||
| N/A | 2 | 1 | 1 | 1 | 5 |
Recruiting Atogepant clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05707949 | KaleidoscopeLong-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine | P3 | Migraine Prophylaxis | 650 | Jun 2023 |
| NCT06810505 | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | P3 | Chronic Migraine | 420 | Feb 2025 |
| NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | P4 | Migraine | 1,335 | Jul 2025 |
| NCT06603558 | Atogepant PMSSPost-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine | — | Chronic Migraine | 3,000 | Sep 2024 |
| NCT05711394 | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | P3 | Episodic Migraine | 450 | May 2023 |
| NCT06212661 | Migraine Medication Effects on Urinary Symptoms | — | Overactive Bladder | 200 | Apr 2024 |
| NCT06882122 | ATOMNeurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine | — | Migraine Disorder | 30 | Dec 2024 |
Atogepant clinical trials by indication
Episodic Migraine (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05711394 | — | P3 | recruiting | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
| NCT04686136 | — | P3 | completed | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine |
| NCT05264129 | TANDEM | P4 | completed | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine |
| NCT04740827 | ELEVATE | P3 | completed | Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. |
| NCT03939312 | — | P3 | completed | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine |
| NCT03777059 | — | P3 | completed | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine |
| NCT03700320 | — | P3 | completed | Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine |
Migraine (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06972056 | — | P4 | recruiting | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study |
| NCT06241313 | ATO ACUTE | P3 | active not recruiting | Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine |
| NCT05748483 | ATO-TOPIRAMATE | P3 | active not recruiting | Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine |
| NCT06414044 | STAR | N/A | active not recruiting | Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients |
| NCT05861427 | JPN PIVOTAL | P3 | completed | Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine |
| NCT04818515 | — | P1 | completed | Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine |
Chronic Migraine (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06810505 | — | P3 | recruiting | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years |
| NCT06603558 | Atogepant PMSS | N/A | recruiting | Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine |
| NCT05216263 | ATO-BOTOX | P3 | completed | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
| NCT04437433 | JPN ATO OLE | P3 | completed | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine |
| NCT04829747 | — | P3 | completed | Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine |
| NCT03855137 | — | P3 | completed | Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine |
Menstrual Migraine (MM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06806293 | ATO MM | P3 | active not recruiting | Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
Migraine Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06882122 | ATOM | N/A | recruiting | Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine |
Migraine, Prophylaxis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06136442 | GIANT | N/A | unknown | Atogepant in Real Life in Italy (GIANT) |
Overactive Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06212661 | — | N/A | enrolling by invitation | Migraine Medication Effects on Urinary Symptoms |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05892757 | — | P1 | completed | Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers |
Migraine Prophylaxis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05707949 | Kaleidoscope | P3 | enrolling by invitation | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine |
Migraine, With or Without Aura (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02848326 | AGN-241689 | P2/P3 | completed | Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention |
Atogepant pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| TANDEM | NCT05264129 | P4 | completed | Episodic Migraine | 263 | PMID 39569702 |
| Kaleidoscope | NCT05707949 | P3 | enrolling by invitation | Migraine Prophylaxis | 650 | — |
| ATO MM | NCT06806293 | P3 | active not recruiting | Menstrual Migraine (MM) | 468 | — |
| ATO ACUTE | NCT06241313 | P3 | active not recruiting | Migraine | 1,300 | PMID 41920093 |
| ATO-TOPIRAMATE | NCT05748483 | P3 | active not recruiting | Migraine | 545 | — |
| ATO-BOTOX | NCT05216263 | P3 | completed | Chronic Migraine | 75 | PMID 41944477 |
| JPN PIVOTAL | NCT05861427 | P3 | completed | Migraine | 524 | PMID 41002192 |
| JPN ATO OLE | NCT04437433 | P3 | completed | Chronic Migraine | 186 | PMID 41814051 |
| ELEVATE | NCT04740827 | P3 | completed | Episodic Migraine | 315 | PMID 38364831 |
All Atogepant trials (26)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05707949 | Kaleidoscope | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine | P3 | enrolling by invitation | 650 | AbbVie | Jun 2023 |
| NCT06810505 | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | P3 | recruiting | 420 | AbbVie | Feb 2025 | |
| NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | P4 | recruiting | 1,335 | Mayo Clinic | Jul 2025 | |
| NCT06603558 | Atogepant PMSS | Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine | — | recruiting | 3,000 | AbbVie | Sep 2024 |
| NCT05711394 | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | P3 | recruiting | 450 | AbbVie | May 2023 | |
| NCT06806293 | ATO MM | Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | P3 | active not recruiting | 468 | AbbVie | Feb 2025 |
| NCT06212661 | Migraine Medication Effects on Urinary Symptoms | — | enrolling by invitation | 200 | The Cleveland Clinic | Apr 2024 | |
| NCT06241313 | ATO ACUTE | Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine | P3 | active not recruiting | 1,300 | AbbVie | Mar 2024 |
| NCT05748483 | ATO-TOPIRAMATE | Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine | P3 | active not recruiting | 545 | AbbVie | Oct 2023 |
| NCT06882122 | ATOM | Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine | — | recruiting | 30 | IRCCS National Neurological Institute "C. Mondino" Foundation | Dec 2024 |
| NCT06414044 | STAR | Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients | — | active not recruiting | 500 | University of Florence | May 2024 |
| NCT04686136 | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | P3 | completed | 596 | AbbVie | Feb 2021 | |
| NCT05216263 | ATO-BOTOX | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | P3 | completed | 75 | AbbVie | Mar 2022 |
| NCT05861427 | JPN PIVOTAL | Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine | P3 | completed | 524 | AbbVie | Jul 2023 |
| NCT06136442 | GIANT | Atogepant in Real Life in Italy (GIANT) | — | unknown | 500 | IRCCS San Raffaele Roma | Apr 2024 |
| NCT04437433 | JPN ATO OLE | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | P3 | completed | 186 | AbbVie | Jun 2020 |
| NCT05892757 | Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers | P1 | completed | 24 | AbbVie | Jul 2023 | |
| NCT05264129 | TANDEM | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine | P4 | completed | 263 | AbbVie | Mar 2022 |
| NCT04740827 | ELEVATE | Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. | P3 | completed | 315 | Allergan | Mar 2021 |
| NCT04829747 | Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine | P3 | completed | 3 | Allergan | Aug 2021 | |
| NCT03855137 | Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine | P3 | completed | 778 | Allergan | Mar 2019 | |
| NCT04818515 | Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine | P1 | completed | 26 | AbbVie | Mar 2021 | |
| NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | P3 | completed | 685 | Allergan | May 2019 | |
| NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | P3 | completed | 910 | Allergan | Dec 2018 | |
| NCT03700320 | Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine | P3 | completed | 744 | Allergan | Oct 2018 | |
| NCT02848326 | AGN-241689 | Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention | P2/P3 | completed | 834 | Allergan | Sep 2016 |
Atogepant clinical trials: frequently asked questions
- How many Atogepant clinical trials are there?
- 26 Atogepant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 14 are marked completed.
- Are Atogepant clinical trials recruiting in 2026?
- Yes — 7 Atogepant trials are actively recruiting in 2026, with 93 U.S. sites across 30 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Atogepant being studied for?
- Atogepant is being studied for Episodic Migraine, Chronic Migraine, Migraine, Menstrual Migraine (MM), Migraine Disorder and 12 more. The trials are grouped by indication on this page.
- What phase is Atogepant in?
- Atogepant clinical trials span 2 Phase 4, 16 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Atogepant clinical trials?
- The lead sponsor across the most Atogepant trials is AbbVie, with 6 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Atogepantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: